Harbor Capital Advisors Inc. Acquires 427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Harbor Capital Advisors Inc. grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 33.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,706 shares of the biotechnology company’s stock after purchasing an additional 427 shares during the period. Harbor Capital Advisors Inc.’s holdings in Sarepta Therapeutics were worth $207,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Sunbelt Securities Inc. increased its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the period. Huntington National Bank grew its stake in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares in the last quarter. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $43,000. UMB Bank n.a. raised its stake in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $59,000. 86.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Guggenheim raised their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday, December 19th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.71.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Performance

SRPT opened at $118.83 on Wednesday. The company has a market cap of $11.35 billion, a P/E ratio of 95.06 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm’s 50-day moving average price is $122.04 and its 200-day moving average price is $130.41. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.